KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Other Non Operating Income: 2010-2025

Historic Other Non Operating Income for Halozyme Therapeutics (HALO) over the last 16 years, with Sep 2025 value amounting to $5.3 million.

  • Halozyme Therapeutics' Other Non Operating Income fell 17.62% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year increase of 20.29%. This contributed to the annual value of $23.8 million for FY2024, which is 45.57% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Other Non Operating Income stood at $5.3 million, which was down 22.61% from $6.9 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Other Non Operating Income high stood at $7.3 million for Q4 2024, and its period low was -$945,000 during Q2 2022.
  • Moreover, its 3-year median value for Other Non Operating Income was $5.3 million (2025), whereas its average is $5.4 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first plummeted by 527.60% in 2022, then skyrocketed by 646.65% in 2023.
  • Halozyme Therapeutics' Other Non Operating Income (Quarterly) stood at $331,000 in 2021, then skyrocketed by 157.40% to $852,000 in 2022, then spiked by 529.11% to $5.4 million in 2023, then surged by 35.32% to $7.3 million in 2024, then decreased by 17.62% to $5.3 million in 2025.
  • Its Other Non Operating Income stands at $5.3 million for Q3 2025, versus $6.9 million for Q2 2025 and $6.8 million for Q1 2025.